Overview

Study of Metastatic Ocular Melanoma

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
This study evaluates treatment with combination versus monotherapy for patients with metastatic ocular melanoma.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Charite University, Berlin, Germany
Treatments:
Gemcitabine
Treosulfan
Criteria
Inclusion Criteria:

- Metastatic ocular melanoma

Exclusion Criteria:

- Prior treatment with chemotherapy

- Active 2nd malignancy

- Cerebral metastasis